个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III NSCLC (TRAILBLAZER): Efficacy, safety and feasibility of surgical conversion outcomes from a proof-of-concept, phase 2 trial

| 认领 | 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Wu, Yi-Long[1] ; Zhou, Qing[1] ; Pan, Yi[1] ; Yang, Xue-Ning[1] ; Zhao, Yanqiu[2] ; Han, Guang[3] ; Pang, Qingsong[4] ; Zhang, Zhenfa[5] ; Wang, Qifeng[6] ; Yao, Jun[7] ; Wang, Hui[8] ; Yang, Weihua[9] ; Liu, Baogang[10] ; Chen, Qixun[11] ; Du, Xianghui[11] ; Cai, Kaican[12] ; Li, Baosheng[13] ; Li, Xiao[14] ; Song, Li[14] ; Shi, Wei[14] ;
机构： [1]Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China [2]Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China [3]Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Wuhan, Peoples R China [4]Tianjin Med Univ, Natl Clin Res Ctr Canc, Canc Inst & Hosp, Tianjin, Peoples R China [5]Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China [6]Univ Elect Sci & Technol China, Sch Med,Sichuan Canc Hosp & Inst, Sichuan Canc Ctr,Dept Radiat Oncol, Radiat Oncol Key Lab Sichuan Prov, Chengdu, Peoples R China [7]Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China [8]Hunan Prov Tumor Hosp, Changsha, Peoples R China [9]Shanxi Prov Canc Hosp, Taiyuan, Peoples R China [10]Harbin Med Univ, Canc Hosp, Harbin, Peoples R China [11]Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China [12]Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China [13]Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Peoples R China [14]Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Jiangsu, Peoples R China
出处：
ISSN：
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China
推荐引用方式(GB/T 7714)：
Wu Yi-Long,Zhou Qing,Pan Yi,et al.Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III NSCLC (TRAILBLAZER): Efficacy, safety and feasibility of surgical conversion outcomes from a proof-of-concept, phase 2 trial[J].JOURNAL OF CLINICAL ONCOLOGY.2024,42(16):
APA：
Wu, Yi-Long,Zhou, Qing,Pan, Yi,Yang, Xue-Ning,Zhao, Yanqiu...&Shi, Wei.(2024).Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III NSCLC (TRAILBLAZER): Efficacy, safety and feasibility of surgical conversion outcomes from a proof-of-concept, phase 2 trial.JOURNAL OF CLINICAL ONCOLOGY,42,(16)
MLA：
Wu, Yi-Long,et al."Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III NSCLC (TRAILBLAZER): Efficacy, safety and feasibility of surgical conversion outcomes from a proof-of-concept, phase 2 trial".JOURNAL OF CLINICAL ONCOLOGY 42..16(2024)

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号